Merck receives positive EU CHMP opinion for Prevymis for prevention of CMV disease in high risk adult kidney transplant recipients and extended 200 day dosing in adult HSCT recipients at risk for late CMV infection and disease

17 October 2023 - Merck today announced that the CHMP of the EMA has recommended the approval of Prevymis (letermovir) for ...

Read more →

GSK receives positive CHMP opinion recommending approval of Jemperli (dostarlimab) plus chemotherapy as a new frontline treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer

16 October 2023 - If approved, dostarlimab would become the first new frontline treatment option in the European Union in ...

Read more →

Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of invasive candidiasis in adults

13 October 2023 - The opinion was based on positive results from the pivotal ReSTORE Phase 3 clinical trial and supported ...

Read more →

Amylyx Pharmaceuticals receives negative CHMP opinion on its marketing authorisation application for AMX0035 for the treatment of ALS in the European Union following re-examination process

13 October 2023 - Final decision from the European Commission expected by the end of 2023. ...

Read more →

BeiGene receives positive CHMP opinion for Brukinsa (zanubrutinib) in relapsed or refractory follicular lymphoma

13 October 2023 - If approved, Brukinsa will be the first and only BTK inhibitor approved for follicular lymphoma. ...

Read more →

New treatment option for heavily pre-treated multiple myeloma patients

13 October 2023 - EMA’s CHMP has recommended a conditional marketing authorisation in the European Union for Elrexfio (elranatamab) as a ...

Read more →

Vueway (gadopiclenol) receives positive CHMP opinion

12 October 2023 - The CHMP of the EMA recommended approval of the macrocyclic, high relaxivity Vueway (gadopiclenol) in adults ...

Read more →

EMA publishes agenda for 9-12 October 2023 CHMP meeting

9 October 2023 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

Takeda receives positive CHMP opinion for Adcetris (brentuximab vedotin) for the treatment of adult patients with previously untreated CD30+ stage III Hodgkin lymphoma in combination with AVD

18 September 2023 - Takeda announced today that the CHMP of the EMA has adopted a positive opinion for the ...

Read more →

CHMP adopts positive opinion to extend the use of Veklury (remdesivir) to treat COVID-19 in people with hepatic impairment

19 September 2023 - This positive opinion reinforces Veklury’s strong safety profile. ...

Read more →

Ebglyss (lebrikizumab) receives positive CHMP opinion for moderate to severe atopic dermatitis

15 September 2023 - Positive opinion is based on Phase 3 studies which showed long-term response in skin clearance and itch ...

Read more →

BioMarin receives positive CHMP opinion in Europe to expand use of Voxzogo (vosoritide) to treat children aged 4 months and older with achondroplasia

15 September 2023 - BioMarin today announced that the EMA's CHMP has adopted a positive opinion recommending marketing authorisation to expand ...

Read more →

Ascendis Pharma receives positive CHMP opinion for TransCon PTH (palopegteriparatide) for adults with chronic hypoparathyroidism

14 September 2023 - Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union ...

Read more →

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

18 September 2023 - Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data. ...

Read more →

Highlights from the 11-14 September 2023 CHMP meeting

15 September 2023 - The EMA’s CHMP recommended nine medicines for approval at its September 2023 meeting. ...

Read more →